Li Xiuze, Liu Jun, Zhou Mengjun, Zhou Chaojing
Int J Clin Pharmacol Ther. 2017 Jul;55(7):601-605. doi: 10.5414/CP202768.
Myoclonus induced by etomidate during induction of general anesthesia is a common phenomenon. This prospective, randomized, saline-controlled clinical study was performed to evaluate the effect of parecoxib sodium pretreatment on the incidence and severity of etomidate-induced myoclonus.
60 patients, American Society of Anesthesiologists (ASA) physical status I or II, aged 20 to 60 years, who were scheduled to undergo elective laparoscopic cholecystectomy under general anesthesia, were allocated randomly into one of two groups to receive parecoxib sodium 40 mg intravenous (group P, n = 30) or the same volume of saline (group S, n = 30) 30 minutes before administration of etomidate (0.3 mg/kg). Myoclonus was assessed on a scale of 0 - 3. Postoperative side effects were recorded.
The two groups were comparable with regard to baseline characteristics. The incidence of myoclonus was significantly lower in the parecoxib sodium group (11/30; 37%) than in the saline group (21/30; 70%) (p < 0.05). The severity of myoclonic movements was also significantly reduced by parecoxib sodium (p < 0.05). There were no significant differences between the two groups with respect to postoperative side effects.
CONCLUSIONS: Pretreatment with intravenous injection of parecoxib sodium 40 mg significantly reduced the incidence and severity of etomidate-induced myoclonus without significant side effects. .
依托咪酯在全身麻醉诱导过程中引起的肌阵挛是一种常见现象。本前瞻性、随机、生理盐水对照的临床研究旨在评估帕瑞昔布钠预处理对依托咪酯诱导的肌阵挛的发生率和严重程度的影响。
60例年龄在20至60岁之间、美国麻醉医师协会（ASA）身体状况为I或II级、计划在全身麻醉下接受择期腹腔镜胆囊切除术的患者，被随机分为两组，在给予依托咪酯（0.3mg/kg）前30分钟，一组静脉注射40mg帕瑞昔布钠（P组，n = 30），另一组注射相同体积的生理盐水（S组，n = 30）。肌阵挛按0 - 3级进行评估。记录术后副作用。
两组在基线特征方面具有可比性。帕瑞昔布钠组的肌阵挛发生率（11/30；37%）显著低于生理盐水组（21/30；70%）（p < 0.05）。帕瑞昔布钠也显著降低了肌阵挛运动的严重程度（p < 0.05）。两组在术后副作用方面无显著差异。
静脉注射40mg帕瑞昔布钠预处理可显著降低依托咪酯诱导的肌阵挛的发生率和严重程度，且无明显副作用。
